Pharmacology Core for Accelerating Safe Antibiotics against Drug-Resistant Infections
Official title: Pharmacology Core
Funded at Hackensack University Medical Center · NIH-11372872 · Data updated 2026-11-12
A core team helps test how new antibiotic candidates behave in the body and in the body’s tissues to reduce drug failures and bring promising treatments for drug-resistant infections closer to patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | June 20, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,458,432 |
| NIH project number | 5U19AI189168-02 |
| Project ID | NIH-11372872 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include patients with high-risk, drug-resistant bacterial infections or those in settings where such pathogens are prevalent and susceptible to new antibiotic options in the pipeline.
✕Less likely to help
Patients not involved in trials or receiving new antibiotics during this phase may not directly benefit from the core's pharmacology profiling activities.
What this research studies
This grant supports a pharmacology core that uses a pharma-style approach to rapidly profile how candidate antibiotics behave in the body, including tissue exposure and safety, to reduce late-stage failures. It provides in vitro and in vivo assessments across multiple drug-resistant pathogens, with a focus on accelerating lead optimization and IND-enabling studies. The work directly informs which compounds should move forward toward preclinical development, aiming to bring effective therapies to people facing serious infections. The core collaborates with multiple CETR projects to ensure timely, rigorous pharmacologic evaluation throughout development.
Why it matters
Potential benefit: If successful, this core could streamline the development of safer and more effective antibiotics for drug-resistant infections, potentially shortening the time to available therapies for patients.
How similar studies have gone: Previous antibiotic development programs show that rigorous PK/PD and safety profiling can improve success rates for translating compounds to the clinic.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Petraitis, Vidmantas — Hackensack University Medical Center
- Study coordinator: Petraitis, Vidmantas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.